Roberta Fruttero

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/825883/publications.pdf

Version: 2024-02-01

156	4,477	117453	149479
papers	citations	34 h-index	56 g-index

163	163	163	5118
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells. Journal of Experimental Medicine, 2011, 208, 1949-1962.	4.2	547
2	Improvement of conventional anti-cancer drugs as new tools against multidrug resistant tumors. Drug Resistance Updates, 2020, 50, 100682.	6.5	160
3	Furoxans as Nitric Oxide Donors. 4-Phenyl-3-furoxancarbonitrile: Thiol-Mediated Nitric Oxide Release and Biological Evaluation. Journal of Medicinal Chemistry, 1994, 37, 4412-4416.	2.9	119
4	Liposome/water lipophilicity: Methods, information content, and pharmaceutical applications. Medicinal Research Reviews, 2004, 24, 299-324.	5.0	100
5	Water Soluble Furoxan Derivatives as NO Prodrugs. Journal of Medicinal Chemistry, 1997, 40, 463-469.	2.9	96
6	Antiinflammatory, Gastrosparing, and Antiplatelet Properties of New NO-Donor Esters of Aspirin. Journal of Medicinal Chemistry, 2003, 46, 747-754.	2.9	92
7	Molecular factors influencing retention on immobilized artifical membranes (IAM) compared to partitioning in liposomes and n-octanol. Pharmaceutical Research, 2002, 19, 729-737.	1.7	85
8	A New Class of Ibuprofen Derivatives with Reduced Gastrotoxicity. Journal of Medicinal Chemistry, 2001, 44, 3463-3468.	2.9	72
9	Synthesis and biological activity of furoxan derivatives against Mycobacterium tuberculosis. European Journal of Medicinal Chemistry, 2016, 123, 523-531.	2.6	64
10	Nitric Oxide Donor Doxorubicins Accumulate into Doxorubicin-Resistant Human Colon Cancer Cells Inducing Cytotoxicity. ACS Medicinal Chemistry Letters, 2011, 2, 494-497.	1.3	63
11	Mitochondrial-Targeting Nitrooxy-doxorubicin: A New Approach To Overcome Drug Resistance. Molecular Pharmaceutics, 2013, 10, 161-174.	2.3	62
12	Folate-targeted liposomal nitrooxy-doxorubicin: An effective tool against P-glycoprotein-positive and folate receptor-positive tumors. Journal of Controlled Release, 2018, 270, 37-52.	4.8	61
13	NO donors: Focus on furoxan derivatives. Pure and Applied Chemistry, 2004, 76, 973-981.	0.9	58
14	NO-Donor COX-2 Inhibitors. New Nitrooxy-Substituted 1,5-Diarylimidazoles Endowed with COX-2 Inhibitory and Vasodilator Properties. Journal of Medicinal Chemistry, 2007, 50, 1449-1457.	2.9	58
15	New praziquantel derivatives containing NO-donor furoxans and related furazans as active agents against Schistosoma mansoni. European Journal of Medicinal Chemistry, 2014, 84, 135-145.	2.6	54
16	Phenylsulfonylfuroxans as Modulators of Multidrug-Resistance-Associated Protein-1 and P-Glycoprotein. Journal of Medicinal Chemistry, 2010, 53, 5467-5475.	2.9	52
17	Mechanism of action of novel NO-releasing furoxan derivatives of aspirin in human platelets. British Journal of Pharmacology, 2006, 148, 517-526.	2.7	51
18	Physicochemical Profiling of Sartans: A Detailed Study of Ionization Constants and Distribution Coefficients. Helvetica Chimica Acta, 2008, 91, 468-482.	1.0	51

#	Article	IF	Citations
19	New 1,4-Dihydropyridines Endowed with NO-Donor and Calcium Channel Agonist Properties. Journal of Medicinal Chemistry, 2004, 47, 2688-2693.	2.9	46
20	NO-Donor Phenols:â€‰ A New Class of Products Endowed with Antioxidant and Vasodilator Properties. Journal of Medicinal Chemistry, 2006, 49, 2886-2897.	2.9	46
21	NO donor and biological properties of different benzofuroxans. Pharmaceutical Research, 1999, 16, 956-960.	1.7	45
22	H₂S-Donating Doxorubicins May Overcome Cardiotoxicity and Multidrug Resistance. Journal of Medicinal Chemistry, 2016, 59, 4881-4889.	2.9	43
23	Design, Synthesis, and Characterization of N-Oxide-Containing Heterocycles with in Vivo Sterilizing Antitubercular Activity. Journal of Medicinal Chemistry, 2017, 60, 8647-8660.	2.9	43
24	Synthesis and Biological Evaluation of the First Example of NO-Donor Histone Deacetylase Inhibitor. ACS Medicinal Chemistry Letters, 2013, 4, 994-999.	1.3	42
25	Unsymmetrically substituted furoxans. Part 16 . Reaction of benzenesulfonyl substituted furoxans with ethanol and ethanethiol in basic medium. Journal of Heterocyclic Chemistry, 1996, 33, 327-334.	1.4	41
26	Hyaluronated liposomes containing H2S-releasing doxorubicin are effective against P-glycoprotein-positive/doxorubicin-resistant osteosarcoma cells and xenografts. Cancer Letters, 2019, 456, 29-39.	3.2	41
27	The Furoxan System as a Useful Tool for Balancing "Hybrids" with Mixed .alpha.1-Antagonist and NO-like Vasodilator Activities. Journal of Medicinal Chemistry, 1995, 38, 4944-4949.	2.9	40
28	Lipophilicity behaviour of the Zwitterionic antihistamine cetirizine in phosphatidylcholine liposomes/water systems. Pharmaceutical Research, 2001, 18, 694-701.	1.7	40
29	Characterization of a new compound, S35b, as a guanylate cyclase activator in human platelets. Biochemical Pharmacology, 1992, 43, 1281-1288.	2.0	39
30	Light-Regulated NO Release as a Novel Strategy To Overcome Doxorubicin Multidrug Resistance. ACS Medicinal Chemistry Letters, 2017, 8, 361-365.	1.3	39
31	Mechanisms of liposomes/water partitioning of (p-methylbenzyl)alkylamines. Pharmaceutical Research, 1998, 15, 1407-1413.	1.7	38
32	Synthesis and Voltage-Clamp Studies of Methyl 1,4-Dihydro-2,6-dimethyl-5-nitro-4-(benzofurazanyl)pyridine-3-carboxylate Racemates and Enantiomers and of Their Benzofuroxanyl Analogues. Journal of Medicinal Chemistry, 1999, 42, 1422-1427.	2.9	38
33	Synthesis, Physicochemical Characterization, and Biological Activities of New Carnosine Derivatives Stable in Human Serum As Potential Neuroprotective Agents. Journal of Medicinal Chemistry, 2011, 54, 611-621.	2.9	36
34	Leishmanicidal Activities of Novel Synthetic Furoxan and Benzofuroxan Derivatives. Antimicrobial Agents and Chemotherapy, 2014, 58, 4837-4847.	1.4	36
35	Edaravone Derivatives Containing NO-Donor Functions. Journal of Medicinal Chemistry, 2009, 52, 574-578.	2.9	35
36	Synthesis and anti-Helicobacter pylori properties of NO-donor/metronidazole hybrids and related compounds. Drug Development Research, 2003, 60, 225-239.	1.4	34

#	Article	IF	Citations
37	Searching for New NO-Donor Aspirin-like Molecules: A New Class of Nitrooxy-acyl Derivatives of Salicylic Acid. Journal of Medicinal Chemistry, 2008, 51, 1894-1903.	2.9	34
38	A new series of amodiaquine analogues modified in the basic side chain with in vitro antileishmanial and antiplasmodial activity. European Journal of Medicinal Chemistry, 2009, 44, 5071-5079.	2.6	34
39	The Furoxan System: Design of Selective Nitric Oxide (NO) Donor Inhibitors of COX-2 Endowed with Anti-Aggregatory and Vasodilating Activities. Chemistry and Biodiversity, 2005, 2, 886-900.	1.0	32
40	(Nitrooxyacyloxy)methyl Esters of Aspirin as Novel Nitric Oxide Releasing Aspirins. Journal of Medicinal Chemistry, 2009, 52, 5058-5068.	2.9	32
41	Novel small molecule protein arginine deiminase 4 (PAD4) inhibitors. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 715-719.	1.0	32
42	Furazan and furoxan sulfonamides are strong Î±-carbonic anhydrase inhibitors and potential antiglaucoma agents. Bioorganic and Medicinal Chemistry, 2014, 22, 3913-3921.	1.4	32
43	A Nonmetalâ€Containing Nitric Oxide Donor Activated with Singleâ€Photon Green Light. Chemistry - A European Journal, 2017, 23, 9026-9029.	1.7	32
44	Unsymmetrically substituted furoxans, XIII. Phenylfuroxancarbaldehydes and related compounds. Liebigs Annalen Der Chemie, 1991, 1991, 1211-1213.	0.8	31
45	Ionic Partition Diagram of the Zwitterionic Antihistamine Cetirizine. Helvetica Chimica Acta, 2001, 84, 375-387.	1.0	31
46	New Nitric Oxide or Hydrogen Sulfide Releasing Aspirins. Journal of Medicinal Chemistry, 2011, 54, 5478-5484.	2.9	31
47	Lightâ€Tunable Generation of Singlet Oxygen and Nitric Oxide with a Bichromophoric Molecular Hybrid: a Bimodal Approach to Killing Cancer Cells. ChemMedChem, 2016, 11, 1371-1379.	1.6	30
48	Amodiaquine analogues containing NO-donor substructures: Synthesis and their preliminary evaluation as potential tools in the treatment of cerebral malaria. European Journal of Medicinal Chemistry, 2011, 46, 1757-1767.	2.6	29
49	New inhibitors of dihydroorotate dehydrogenase (DHODH) based on the 4-hydroxy-1,2,5-oxadiazol-3-yl (hydroxyfurazanyl) scaffold. European Journal of Medicinal Chemistry, 2012, 49, 102-109.	2.6	29
50	Liposomal Nitrooxy-Doxorubicin: One Step over Caelyx in Drug-Resistant Human Cancer Cells. Molecular Pharmaceutics, 2014, 11, 3068-3079.	2.3	29
51	Studies on agents with mixed NO-dependent vasodilating and beta-blocking activities. Pharmaceutical Research, 1997, 14, 1750-1758.	1.7	28
52	Hydroxy-1,2,5-oxadiazolyl Moiety as Bioisoster of the Carboxy Function. Synthesis, Ionization Constants, and Pharmacological Characterization of Î³-Aminobutyric Acid (GABA) Related Compounds. Journal of Medicinal Chemistry, 2006, 49, 4442-4446.	2.9	28
53	A novel hybrid aspirin-NO-releasing compound inhibits TNFalpha release from LPS-activated human monocytes and macrophages. Journal of Inflammation, 2008, 5, 12.	1.5	28
54	1,2,5-Oxadiazole analogues of leflunomide and related compounds. European Journal of Medicinal Chemistry, 2011, 46, 383-392.	2.6	28

#	Article	IF	Citations
55	Designing Multitarget Antiâ€inflammatory Agents: Chemical Modulation of the Lumiracoxib Structure toward Dual Thromboxane Antagonistsâ€“COXâ€2 Inhibitors. ChemMedChem, 2012, 7, 1647-1660.	1.6	28
56	Searching for new NO-donor aspirin-like molecules: Furoxanylacyl derivatives of salicylic acid and related furazans. Bioorganic and Medicinal Chemistry, 2011, 19, 5852-5860.	1.4	27
57	Doxorubicin-antioxidant co-drugs. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 5307-5310.	1.0	27
58	Synthesis of new bicyclic analogues of glutamic acid. Tetrahedron, 1999, 55, 5623-5634.	1.0	26
59	Unsymmetrically substituted furoxans. Part 18. Smiles rearrangement in furoxan systems and in related furazans. Journal of the Chemical Society, Perkin Transactions 1, 2001, , 1751-1757.	1.3	26
60	Michael addition of Grignard reagents to tetraethyl ethenylidenebisphosphonate. Journal of Organometallic Chemistry, 2002, 650, 77-83.	0.8	26
61	Nitric Oxide Donor Î²₂-Agonists:â€‰ Furoxan Derivatives Containing the Fenoterol Moiety and Related Furazans. Journal of Medicinal Chemistry, 2007, 50, 5003-5011.	2.9	26
62	Fluorescent Nitric Oxide Photodonors Based on BODIPY and Rhodamine Antennae. Chemistry - A European Journal, 2019, 25, 11080-11084.	1.7	26
63	Design, Biological Evaluation, and Molecular Modeling of Tetrahydroisoquinoline Derivatives: Discovery of A Potent P-Glycoprotein Ligand Overcoming Multidrug Resistance in Cancer Stem Cells. Journal of Medicinal Chemistry, 2019, 62, 974-986.	2.9	26
64	Development of a new class of potential antiatherosclerosis agents: NO-donor antioxidants. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 5971-5974.	1.0	25
65	4-Hydroxy-1,2,5-oxadiazol-3-yl Moiety as Bioisoster of the Carboxy Function. Synthesis, Ionization Constants, and Molecular Pharmacological Characterization at Ionotropic Glutamate Receptors of Compounds Related to Glutamate and Its Homologues. Journal of Medicinal Chemistry, 2010, 53, 4110-4118.	2.9	24
66	Overcoming multidrug resistance by targeting mitochondria with NO-donating doxorubicins. Bioorganic and Medicinal Chemistry, 2016, 24, 967-975.	1.4	24
67	[3-(1 H -Imidazol-4-yl)propyl]guanidines containing furoxan moieties. Bioorganic and Medicinal Chemistry, 2003, 11, 1197-1205.	1.4	22
68	Synthesis of NO-Donor Bisphosphonates and Their in-Vitro Action on Bone Resorption. Journal of Medicinal Chemistry, 2005, 48, 1322-1329.	2.9	22
69	Synthesis and preliminary pharmacological characterisation of a new class of nitrogen-containing bisphosphonates (N-BPs). Bioorganic and Medicinal Chemistry, 2010, 18, 2428-2438.	1.4	22
70	Synthesis and in vitro antimicrobial activities of new (cyano-NNO-azoxy)pyrazole derivatives. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 3431-3434.	1.0	22
71	A Nitric Oxide-Donor Furoxan Moiety Improves the Efficacy of Edaravone against Early Renal Dysfunction and Injury Evoked by Ischemia/Reperfusion. Oxidative Medicine and Cellular Longevity, 2015, 2015, 1-12.	1.9	22
72	A molecular hybrid producing simultaneously singlet oxygen and nitric oxide by single photon excitation with green light. Bioorganic Chemistry, 2019, 85, 18-22.	2.0	22

#	Article	IF	Citations
73	Chemical and biological studies on calvatic acid and its analogs.. Journal of Antibiotics, 1986, 39, 864-868.	1.0	21
74	Unsymmetrically substituted furoxans, XII. Phenylfuroxancarboxylic acids and their derivatives. Liebigs Annalen Der Chemie, 1990, 1990, 335-338.	0.8	21
75	Unsymmetrically Substituted Furoxans, XIV. Synthesis and Structure of a Trimer of the Furoxan System with High Vasodilator and Platelet Antiaggregatory Activity. Liebigs Annalen Der Chemie, 1993, 1993, 441-444.	0.8	21
76	Synthesis and preliminary biological profile of new NO-donor tolbutamide analogues. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 3810-3815.	1.0	21
77	NO-donor thiacarbocyanines as multifunctional agents for Alzheimerâ€™s disease. Bioorganic and Medicinal Chemistry, 2015, 23, 4688-4698.	1.4	21
78	Waterâ€Soluble Nitricâ€Oxideâ€Releasing Acetylsalicylic Acid (ASA) Prodrugs. ChemMedChem, 2013, 8, 1199-1209.	1.6	20
79	Structureâ€“Activity Relationship Studies on Tetrahydroisoquinoline Derivatives: [4â€²-(6,7-Dimethoxy-3,4-dihydro-1H-isoquinolin-2-ylmethyl)biphenyl-4-ol] (MC70) Conjugated through Flexible Alkyl Chains with Furazan Moieties Gives Rise to Potent and Selective Ligands of P-glycoprotein. Journal of Medicinal Chemistry, 2016, 59, 6729-6738.	2.9	20
80	Furoxan Nitric Oxide Donors Disperse Pseudomonas aeruginosa Biofilms, Accelerate Growth, and Repress Pyoverdine Production. ACS Chemical Biology, 2017, 12, 2097-2106.	1.6	20
81	Synthesis and vasodilating properties of N-alkylamide derivatives of 4-amino-3-furoxancarboxylic acid and related azo derivatives. Il Farmaco, 2003, 58, 677-681.	0.9	19
82	A New Furoxan NO-Donor Rabeprazole Derivative and Related Compounds. ChemBioChem, 2003, 4, 899-903.	1.3	19
83	Multitarget drugs: Focus on the NO-donor hybrid drugs. Pure and Applied Chemistry, 2008, 80, 1693-1701.	0.9	19
84	The role of fluorine in stabilizing the bioactive conformation of dihydroorotate dehydrogenase inhibitors. Journal of Molecular Modeling, 2013, 19, 1099-1107.	0.8	19
85	NO-Donor Dihydroartemisinin Derivatives as Multitarget Agents for the Treatment of Cerebral Malaria. Journal of Medicinal Chemistry, 2015, 58, 7895-7899.	2.9	18
86	Structural and biological characterization of new hybrid drugs joining an HDAC inhibitor to different NO-donors. European Journal of Medicinal Chemistry, 2018, 144, 612-625.	2.6	18
87	Nitrooxymethylâ€Substituted Analogues of Rofecoxib: Synthesis and Pharmacological Characterization. Chemistry and Biodiversity, 2010, 7, 1173-1182.	1.0	17
88	Oximation of acetyl(hydroxyimino)acetone: nuclear magnetic resonance spectroscopic, chemical, and X-ray crystallographic studies of the reaction products. Journal of the Chemical Society Perkin Transactions II, 1987, , 523.	0.9	16
89	Novel antioxidant agents deriving from molecular combination of Vitamin C and NO-donor moieties. Bioorganic and Medicinal Chemistry, 2008, 16, 5199-5206.	1.4	16
90	6-Cyclohexylmethoxy-5-(cyano-NNO-azoxy)pyrimidine-4-amine: AÂnew scaffold endowed with potent CDK2 inhibitory activity. European Journal of Medicinal Chemistry, 2013, 68, 333-338.	2.6	16

#	Article	IF	Citations
91	A directed synthesis of alkyl, aryl, and heteroaryl-ONN-azoxycyanides. Journal of the Chemical Society Chemical Communications, 1984, , 323.	2.0	15
92	Mesomeric dipole moments. Part 12. Structural Chemistry, 1990, 1, 417-421.	1.0	15
93	Studies on agents with mixed NO-dependent and calcium channel antagonistic vasodilating activities. Pharmaceutical Research, 2001, 18, 157-165.	1.7	15
94	New tetrahydroisoquinoline-based P-glycoprotein modulators: decoration of the biphenyl core gives selective ligands. MedChemComm, 2018, 9, 862-869.	3.5	15
95	A generator of peroxynitrite activatable with red light. Chemical Science, 2021, 12, 4740-4746.	3.7	15
96	Dipole moments and electron distribution of furoxans and furazans. Journal of Molecular Structure, 1994, 324, 277-282.	1.8	14
97	Searching for balanced hybrid NO-donor 1,4-dihydropyridines with basic properties. Pharmaceutical Research, 2001, 18, 987-991.	1.7	14
98	New Potential Uroselective NO-Donor Î±1-Antagonists. Journal of Medicinal Chemistry, 2003, 46, 3762-3765.	2.9	14
99	Furoxan analogues of the histamine H3-receptor antagonist imoproxifan and related furazan derivatives. Bioorganic and Medicinal Chemistry, 2005, 13, 4750-4759.	1.4	14
100	Nitrooxymethylâ€Substituted Analogues of Celecoxib: Synthesis and Pharmacological Characterization. Chemistry and Biodiversity, 2009, 6, 369-379.	1.0	14
101	Carnosine analogues containing NO-donor substructures: Synthesis, physico-chemical characterization and preliminary pharmacological profile. European Journal of Medicinal Chemistry, 2012, 54, 103-112.	2.6	14
102	Î±1-Adrenoceptor Blocking Activity of Some Ring-open Analogues of Prazosin. Archiv Der Pharmazie, 1994, 327, 661-667.	2.1	13
103	Nicorandil analogues containing NO-donor furoxans and related furazans. Bioorganic and Medicinal Chemistry, 2000, 8, 1727-1732.	1.4	13
104	The Lipophilicity Behavior of Three Catechol-O-methyltransferase (COMT) Inhibitors and Simple Analogues. Helvetica Chimica Acta, 2006, 89, 144-152.	1.0	13
105	NO-donor melatonin derivatives: synthesis and in vitro pharmacological characterization. Journal of Pineal Research, 2007, 42, 371-385.	3.4	13
106	A multi-photoresponsive molecular-hybrid for dual-modal photoinactivation of cancer cells. RSC Advances, 2014, 4, 44827-44836.	1.7	13
107	A Potent and Selective Pâ€gp Modulator for Altering Multidrug Resistance Due to Pump Overexpression. ChemMedChem, 2016, 11, 374-376.	1.6	13
108	New Tetrahydroisoquinoline Derivatives Overcome Pgp Activity in Brain-Blood Barrier and Glioblastoma Multiforme in Vitro. Molecules, 2018, 23, 1401.	1.7	13

#	Article	IF	Citations
109	One molecule two goals: A selective P-glycoprotein modulator increases drug transport across gastro-intestinal barrier and recovers doxorubicin toxicity in multidrug resistant cancer cells. European Journal of Medicinal Chemistry, 2020, 208, 112843.	2.6	13
110	Electrochemical studies of biologically active arylazoxy compounds. The relationship between redox potentials and molluscicidal activities. Journal of Electroanalytical Chemistry, 2003, 544, 25-34.	1.9	12
111	A new class of NO-donor H3-antagonists. Il Farmaco, 2004, 59, 359-371.	0.9	12
112	Novel R-roscovitine NO-donor hybrid compounds as potential pro-resolution of inflammation agents. Bioorganic and Medicinal Chemistry, 2013, 21, 2107-2116.	1.4	12
113	Nitroanilines are the reduction products of benzofuroxan system by oxyhemoglobin (HbO22+). Il Farmaco, 2001, 56, 799-802.	0.9	11
114	Synthesis physicochemical profile and PAMPA study of new NO-donor edaravone co-drugs. Bioorganic and Medicinal Chemistry, 2012, 20, 841-850.	1.4	11
115	A Molecular Hybrid for Mitochondriaâ€Targeted NO Photodelivery. ChemMedChem, 2018, 13, 87-96.	1.6	11
116	MRP5 nitration by NO-releasing gemcitabine encapsulated in liposomes confers sensitivity in chemoresistant pancreatic adenocarcinoma cells. Biochimica Et Biophysica Acta - Molecular Cell Research, 2020, 1867, 118824.	1.9	11
117	13C and 15N solution and solid-state nuclear magnetic resonance study of the intermolecular interactions in the 1 : 1 trimethoprim sulphamethoxazole complex. Journal of the Chemical Society Perkin Transactions II, 1988, , 1863.	0.9	10
118	Reversed-phase high-performance liquid chromatographic study of the lipophilicity of a series of analogues of the antibiotic â€œcalvatic acidâ€• Journal of Chromatography A, 1991, 547, 167-173.	1.8	10
119	Evidence of self-protonation on the electrodic reduction mechanism of an anti-Helicobacter pylori metronidazole isotere. Journal of Electroanalytical Chemistry, 2004, 571, 177-182.	1.9	10
120	Unsymmetrically substituted furoxans. Part 19. Methyl and phenylfuroxansulfonic acids and related sulfonamides. Journal of Heterocyclic Chemistry, 2009, 46, 866-872.	1.4	10
121	In vitro pharmacological evaluation of multitarget agents for thromboxane prostanoid receptor antagonism and COX-2 inhibition. Pharmacological Research, 2016, 103, 132-143.	3.1	10
122	Combination of PDT and NOPDT with a Tailored BODIPY Derivative. Antioxidants, 2019, 8, 531.	2.2	10
123	Molecular-Dynamics and NMR Investigation of the Property Space of the Zwitterionic Antihistamine Cetirizine. Helvetica Chimica Acta, 2001, 84, 360-374.	1.0	9
124	Tuning the Hydrophobicity of a Mitochondriaâ€Targeted NO Photodonor. ChemMedChem, 2018, 13, 1238-1245.	1.6	9
125	Discovery of phenylsulfonylfuroxan derivatives as gamma globin inducers by histone acetylation. European Journal of Medicinal Chemistry, 2018, 154, 341-353.	2.6	9
126	Inhibition of Human Placenta Glutathione Transferase Pl-1 by the Antibiotic Calvatic Acid and its Diazocyanide Analogue. Evidence for Multiple Catalytic Intermediates. FEBS Journal, 1997, 245, 663-667.	0.2	8

#	Article	IF	Citations
127	Structure-Property Relationships in the Basicity and Lipophilicity of Arylalkylamine Oxides. Helvetica Chimica Acta, 1999, 82, 1630-1639.	1.0	8
128	Synthesis of Some Novel Organic Nitrates and Comparative in Vitro Study of Their Vasodilator Profile. Journal of Medicinal Chemistry, 2009, 52, 4020-4025.	2.9	8
129	Thymopentin down-regulates both activity and expression of iNOS in blood cells of SÃ©zary syndrome patients. Nitric Oxide - Biology and Chemistry, 2012, 27, 143-149.	1.2	8
130	Tuning NO release of organelle-targeted furoxan derivatives and their cytotoxicity against lung cancer cells. Bioorganic Chemistry, 2021, 111, 104911.	2.0	8
131	Acyclic analogs of classical H2-antagonists: synthesis and activity of dialkylamioalkyl substituted ethers and oximes. European Journal of Medicinal Chemistry, 1987, 22, 255-259.	2.6	7
132	Nitrooxyacyl Derivatives of Salicylic Acid: Aspirinâ€Like Molecules that Covalently Inactivate Cyclooxygenaseâ€1. ChemMedChem, 2011, 6, 523-530.	1.6	7
133	Synthesis, chiral HPLC resolution and configuration assignment of 1-phenylglyceryl trinitrate stereomers. Chirality, 2006, 18, 430-436.	1.3	6
134	Structure-Antioxidant Activity Relationships in a Series of NO-Donor Phenols. ChemMedChem, 2008, 3, 1443-1448.	1.6	6
135	A Rapid Screening for Cytochrome P450 Catalysis on New Chemical Entities: Cytochrome P450 BM3 and 1,2,5-Oxadiazole Derivatives. Journal of Biomolecular Screening, 2013, 18, 211-218.	2.6	6
136	Synthesis and Biological Evaluation of N2-Substituted 2,4-Diamino-6-cyclohexylmethoxy-5-nitrosopyrimidines and Related 5-Cyano-NNO-azoxy Derivatives as Cyclin-Dependent Kinaseâ€…2 (CDK2) Inhibitors. ChemMedChem, 2016, 11, 1705-1708.	1.6	6
137	Electronic and Hydrophobic Constants of Azoxy Groups Containing Electron Withdrawing Functions. QSAR and Combinatorial Science, 1988, 7, 26-30.	1.4	5
138	Inhibition of Human Î±-, Î²- and Î³-Thrombin by mono-, bis-, tris- and tetra-Benzamidine Structures: Thermodynamic Study. Journal of Enzyme Inhibition and Medicinal Chemistry, 1992, 6, 131-139.	0.5	5
139	The relationship between redox potentials and substituent constants in biologically active arylazoxy compounds. Journal of Electroanalytical Chemistry, 2005, 579, 33-41.	1.9	5
140	Non-imidazole histamine NO-donor H3-antagonists. Il Farmaco, 2005, 60, 507-512.	0.9	5
141	NO release regulated by doxorubicin as the green light-harvesting antenna. Chemical Communications, 2020, 56, 6332-6335.	2.2	5
142	In vitro vascular toxicity assessment of NitDOX, a novel NO-releasing doxorubicin. European Journal of Pharmacology, 2020, 880, 173164.	1.7	5
143	NO in Viral Infections: Role and Development of Antiviral Therapies. Molecules, 2022, 27, 2337.	1.7	5
144	Platelet antiaggregatory effects and haemodynamic activity of two terfuroxan isomer pairs. Il Farmaco, 2002, 57, 417-420.	0.9	4

#	Article	IF	Citations
145	gem-Dinitroalkyl Benzenes: A Novel Class of IOP-Lowering Agents for the Treatment of Ocular Hypertension. ACS Medicinal Chemistry Letters, 2017, 8, 1054-1059.	1.3	4
146	Thermolysis of 4-(2-azido-3-nitrophenyl)-1,4-dihydropyridines as source of Î²-carboline derivatives and some related compounds. Tetrahedron Letters, 2001, 42, 4507-4510.	0.7	3
147	On the self-condensation of aminoguanidine leading to 1,1,4,10,10-pentaamino-2,3,5,6,8,9-hexaazadeca-1,3,5,7,9-pentaene (structure elucidation through X-ray) Tj ETQq1 1 0.784314 rgBT /O	1.1	3
148	Electronic Substituent Effects of Furoxan and Furazan Systems. Journal of Chemical Research Synopses, 1998, , 495-495.	0.3	2
149	Amphiphilic NO-Donor Antioxidants. ChemMedChem, 2007, 2, 234-240.	1.6	2
150	Multitarget Drugs: Synthesis and Preliminary Pharmacological Characterization of Zileuton Analogues Endowed with Dual 5â€LO Inhibitor and NOâ€Dependent Activities. ChemMedChem, 2010, 5, 1444-1449.	1.6	2
151	DNAâ€Targeted NO Release Photoregulated by Green Light. Chemistry - A European Journal, 2020, 26, 13627-13633.	1.7	2
152	Physicochemical profile and in vitro permeation behavior of a new class of non-steroidal anti-inflammatory drug candidates. European Journal of Pharmaceutical Sciences, 2010, 40, 217-221.	1.9	1
153	Liposome/Water Lipophilicity: Methods, Information Content, and Pharmaceutical Applications. ChemInform, 2004, 35, no.	0.1	0
154	A New Class of NO-Donor H3-Antagonists.. ChemInform, 2004, 35, no.	0.1	0
155	Development of a New Class of Potential Antiatherosclerosis Agents: NO-Donor Antioxidants.. ChemInform, 2005, 36, no.	0.1	0
156	Molecular dynamics simulations reveal the determinants of cyclin-dependent kinase 2 inhibition by 5-nitrosopyrimidine derivatives. Journal of Biomolecular Structure and Dynamics, 2020, 38, 4016-4024.	2.0	0